金黄色葡萄球菌耐消毒剂基因及抗生素耐药相关基因检测

目的 了解温州地区临床分离的金黄色葡萄球菌(SA)的耐药特点,探讨SA中耐β-内酰胺类、氨基糖苷类、四环素类药物耐药基因及耐消毒剂基因(qacA)的存在情况.方法 采用聚合酶链式反应(PCR)法对SA进行β-内酰胺酶基因、氨基糖苷类修饰酶基因、四环素类基因和耐消毒剂基因检测.结果 PCR结果显示94株SA中耐药相关基因检出率mecA 53.2％、aac(6’)/aph(2")68.1％、aph(3’)-Ⅲ 37.2％、tetM 53.2％和qacA 7.4％,其中59株MRSA的耐药相关基因检出率分别为mecA 83.1％、aac(6’)/aph(2")86.4％、aph(3 ′)-Ⅲ 42.4％、tetM 76.4％和qacA 8.5％.结论 多数SA菌株存在耐β-内酰胺类、氨基糖苷类、四环素类等多种抗生素耐药基因,具有多重耐药特征,但尚未出现明显耐消毒剂状况.     

禽源多重耐药金黄色葡萄球菌耐药基因检测及分子分型

【背景】金黄色葡萄球菌是革兰氏阳性菌,在动物和人身上能引起一系列疾病。【目的】了解安徽省不同地区禽源多重耐药金黄色葡萄球菌耐药性的情况及基因分型特征。【方法】以安徽不同地区的病禽肝脏作为标本,分离鉴定得到103株多重耐药金黄色葡萄球菌,并进行耐药基因型检测和ERIC-PCR分子分型。【结果】耐药菌株从三重到八重耐药均有分布,主要集中在五重(43/103)、四重(21/103)和六重耐药(22/103)。药敏结果显示,β-内酰胺类的耐药率最高(79.6%),氨基糖苷类次之(71.8%)。耐药基因检出率由高到低分别为mec A(92.2%)、aac(6′)/aph(2″)(76.7%)、ermC(37.9%)、ermA(13.6%)和fem A(3.9%)。ERIC-PCR分子分型获得6种不同类群,优势流行菌群为类群Ⅱ(38/103)。【结论】安徽地区金黄色葡萄球菌存在较严重的耐药性,氨基糖苷类、β-内酰胺类和大环内酯类抗生素的耐药基因携带率较高。分型结果表明安徽部分区域耐药金黄色葡萄球菌具有遗传多样性,但耐药谱与ERIC-PCR分子分型无明显关联。     

金黄色葡萄球菌L型耐药调查

１９９０年至１９９４年从临床送检的骨髓和血标本中分离出金黄色葡萄球菌（下标金葡菌）Ｌ型１７７株,本文将其耐药性逐年加以比较,以便临床医务工作者合理选用抗菌药物作为参考,从而减少耐药菌株的产生,提高治愈率。     

金黄色葡萄球菌耐药机制的研究进展

多征重耐药性金黄金葡萄球感染越来越引起临床重视。细菌产生β－内酰胺酶是对β－内酰按蟠蠊生素是最主要耐药机制,不产酶株主要是细菌合成新型青霉素结合蛋白２ａ而引起抗生素作用靶位改变之故,它由获得性染色体基因所编码。     

对万古霉素敏感性下降的金黄色葡萄球菌研究进展

随着MRSA的越发,万古霉素在临床上的使用越来越频繁,成为治疗MRSA的最后一道防线;然而,对万古霉素敏感性下降的金黄色葡萄球菌的出现,临床上抗感染治疗面临极大困难,引起了医学界普遍的关注。本文对万古霉素敏感性下降的金黄色葡萄球菌的发展,耐药状况,作用机制,相关治疗和热门争议话题等方面的研究进展作一综述。     

对万古霉素敏感性下降的金黄色葡萄球菌研究进展

随着MRSA的越发,万古霉素在临床上的使用越来越频繁,成为治疗MRSA的最后一道防线;然而,对万古霉素敏感性下降的金黄色葡萄球菌的出现,临床上抗感染治疗面临极大困难,引起了医学界普遍的关注。本文对万古霉素敏感性下降的金黄色葡萄球菌的发展,耐药状况,作用机制,相关治疗和热门争议话题等方面的研究进展作一综述。     

金黄色葡萄球菌耐药性变迁

为了解 1 999～ 2 0 0 3年临床分离金黄色葡萄球菌耐药性的变迁情况 ,采用K B方法和微量肉汤稀释法 ,对 1 999年 1月至 2 0 0 3年 1 2月临床分离的 42 3株金黄色葡萄球菌进行药敏试验 ;耐药率的显著性比较采用x2 检验。结果显示 ,1 999～ 2 0 0 3年从临床送检标本中共分离出金黄色葡萄球菌 42 3株。 2 0 0 2～ 2 0 0 3年MRSA的分离率为 1 9.7% (2 9/ 1 47)有增加趋势 ,高于 1 999～ 2 0 0 0年度分离率 1 7.5 % (3 3 / 1 89)。在 2 0 0 2～2 0 0 3年间MSSA对头孢吡肟、环丙沙星、左旋氧氟沙星、复方新诺明、氯霉素和庆大霉素的耐药率分别为0 .0 % ,4.6% ,2 .3 % ,1 .3 % ,6.8%和 2 1 .8%。而对青霉素、红霉素和克林霉素耐药率较高 ,为 5 1 .9% ,70 .4%和 41 .3 %。与 1 999～ 2 0 0 0年比较 ,MSSA对青霉素G、环丙沙星、四环素和复方新诺明的耐药率明显下降 ,p <0 .0 5。 5a间未发现耐万古霉素和替考拉宁菌株。 1 999～ 2 0 0 3年MRSA发生率有增加趋势。耐药性监测有助于遏制抗菌药物的耐药问题。     

耐甲氧西林金黄色葡萄球菌消毒剂和抗生素耐药相关基因的聚类分析

目的了解解放军第98医院临床分离的耐甲氧西林金黄色葡萄球菌(MRSA)抗菌药物耐药基因存在状况及菌株亲缘性。方法采用聚合酶链反应及序列分析的方法检测50株MRSA中10种耐药相关基因,采用Average法对耐药基因进行聚类分析。结果50株MRSA中m ecA、aac(6')-aph(2')、tetM和erm基因均阳性,qacA、blaTEM、aph(3')-III和ant(4',4')基因阳性率分别为92.0%、40.0%、98.0%和4.0%,vanA和vanB基因均阴性。在1号、2号、3号菌株的qacA基因序列编码区域同一位点均有1个碱基发生有义突变(G→A),相应的苏氨酸(T)被异亮氨酸(I)所取代。根据耐药基因的聚类分析该50株MRSA可分为2个亚群,为院内感染所致。结论临床分离的MRSA耐药相关基因携带率很高;qacA基因存在有义突变为新的发现;MRSA可导致克隆传播院内感染,并存在暴发性流行。     

金黄色葡萄球菌基因调节系统研究进展

金黄色葡萄球菌是人类的一种重要病原菌,可以引起许多临床表现不同的感染性疾病。它所致感染的多样性和严重度取决于不同毒力因子的协同表达,而这些数量众多的毒力因子的表达会受到不同调节系统的控制,同时这些调节系统之间也存在着复杂的相互作用关系。这些基因调节系统主要有两大类：一类是双组分信号转导系统（如Agr、SaeRS、SrrAB、ArlSR、LytRS、WalKR）;另一类是转录因子f如Sar、Rot、MgrA、SigmaB）。它们的协同作用有助于金黄色葡萄球菌对外界环境信号做出反应,调节致病过程中毒力因子在不同情况下的表达。     

In vitro anti- biofilm and anti-bacterial activity of Sesbania grandiflora extract against Staphylococcus aureus

The main objective of this research is to investigate the anti-biofilm and anti-bacterial activity of Sesbania grandiflora (S. grandiflora) against Staphylococcus aureus. S. grandiflora extract were prepared and analyzed with UV –Vis spectroscopy, Fourier transform infrared spectroscopy, Dynamic light scattering. Biofilm forming pathogens were identified by congo-red assay. Quantification of Extracellular polymeric substance (EPS) particularly protein and carbohydrate were calculated. The efficacy of the herbal extract S. grandiflora and its inhibition against the pathogenic strain of S. aureus was also evaluated. The gradual decrease or disappearance of peaks reveals the reduction of protein and carbohydrate content in the EPS of S. aureus when treated with S. grandiflora. The antibacterial activity of S. grandiflora extract against the bacterial strain S. aureus showed that the extract were more active against the strain. To conclude, anti-biofilm and antibacterial efficacy of S. grandiflora plays a vital role over biofilm producing pathogens and act as a good source for controlling the microbial population.     

Promising antibacterial agents against multidrug resistant Staphylococcus aureus

Rapid emergence of multidrug resistant Staphylococcus aureus infections has created a critical health menace universally. Resistance to all the available chemotherapeutics has been on rise which led to WHO to stratify Staphylococcus aureus as high tier priorty II pathogen. Hence, discovery and development of new antibacterial agents with new mode of action is crucial to address the multidrug resistant Staphylococcus aureus infections. The egressing understanding of new antibacterials on their biological target provides opportunities for new therapeutic agents. This review underlines on various aspects of drug design, structure activity relationships (SARs) and mechanism of action of various new antibacterial agents and also covers the recent reports on new antibacterial agents with potent activity against multidrug resistant Staphylococcus aureus. This review provides attention on in vitro and in vivo pharmacological activities of new antibacterial agents in the point of view of drug discovery and development.     

Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA.     

Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of Staphylococcus aureus

The synthesis of symmetric and asymmetric piperazinyl-linked dimers of the fluoroquinolone class of antibiotics is described. Specific dimers are shown to possess potent antibacterial activity against drug-resistant strains of Staphylococcus aureus, including strains possessing resistance due to the NorA multidrug efflux pump and a mutation in the quinolone resistance-determining region of topoisomerase IV.     

Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus

We previously demonstrated that piperazinyl-linked fluoroquinolone dimers possess potent antibacterial activity against drug-resistant strains of Staphylococcus aureus. In this study, we report the preparation and evaluation of a series of incomplete dimers toward ascertaining structural features of piperazinyl-linked ciprofloxacin dimers that render these agents refractory to fluoroquinolone-resistance mechanisms in Staphylococcus aureus.     

Pentadecanal inspired molecules as new anti-biofilm agents against Staphylococcus epidermidis

Abstract

Staphylococcus epidermidis, a harmless human skin colonizer, is a significant nosocomial pathogen in predisposed hosts because of its capability to form a biofilm on indwelling medical devices. In a recent paper, the purification and identification of the pentadecanal produced by the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125, able to impair S. epidermidis biofilm formation, were reported. Here the authors report on the chemical synthesis of pentadecanal derivatives, their anti-biofilm activity on S. epidermidis, and their action in combination with antibiotics. The results clearly indicate that the pentadecanal derivatives were able to prevent, to a different extent, biofilm formation and that pentadecanoic acid positively modulated the antimicrobial activity of the vancomycin. The cytotoxicity of these new anti-biofilm molecules was tested on two different immortalized eukaryotic cell lines in view of their potential applications.     

Molecular design of multifunctional antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA)

Antibacterial activity of a series of alkyl gallates (3,4,5-trihydroxybenzoates) against Gram-positive bacteria, especially methicillin resistant Staphylococcus aureus (MRSA) strains was evaluated. Gram-positive bacteria are all susceptible to alkyl gallates. Dodecyl gallate was the most effective against MRSA ATCC 33591 strain with the minimum bactericidal concentration (MBC) of 25 microg/mL (74 microM). The time-kill curve study showed that dodecyl gallate was bactericidal against this MRSA strain at any growth stage. This activity was observed even in the chloramphenicol-treated cells, but the rate of decrease of cell number was slower than that in the exponentially growing cells. The bactericidal activity of medium-chain alkyl gallates was noted in combination with their ability to disrupt the native membrane-associated function nonspecifically as surface-active agents (surfactants) and to inhibit the respiratory electron transport. Subsequently, the same series of alkyl protocatechuates (3,4-dihydroxybenzoates) were studied and the results obtained are similar to those found for alkyl gallates. The length of the alkyl chain is not a major contributor but is related to the activity.     

金黄色葡萄球菌疫苗及其免疫治疗进展

具有多重抗生素耐药性的金黄色葡萄球菌是导致医院感染最常见的致病菌,而目前高致病性耐甲氧西林菌株(MRSA)在社区中的传播使得健康人群也面临极大威胁,因此针对金黄色葡萄球菌的疫苗和免疫治疗的研究迫在眉睫。多数的研究以金黄色葡萄球菌细胞壁锚定蛋白、荚膜多糖、外毒素等为靶点,虽然在一些临床前试验中显示出疫苗和免疫治疗对金葡菌感染具有保护性,但是目前临床试验结果却并不乐观,还没有一个经得起临床检验的疫苗。本文章从临床前试验和临床试验两个方面综述了目前关于金黄色葡萄球菌的疫苗和免疫治疗进展。     

Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus

Bacteria of the genus Staphylococcus are common pathogens responsible for a broad spectrum of human and animal infections and belong to the most important etiological factors causing food poisoning. Because of rapid increase in the prevalence of isolation of staphylococci resistant to many antibiotics, there is an urgent need for the development of new alternative chemotherapeutics. A number of studies have recently demonstrated the strong potential of peptidoglycan hydrolases (PHs) to control and treat infections caused by this group of bacteria. PHs cause rapid lysis and death of bacterial cells. The review concentrates on enzymes hydrolyzing peptidoglycan of staphylococci. Usually, they are characterized by high specificity to only Staphylococcus aureus cell wall components; however, some of them are also able to lyse cells of other staphylococci, e.g., Staphylococcus epidermidis-human pathogen of growing importance and also other groups of bacteria. Some PHs strengthen the bactericidal or bacteriostatic activity of common antibiotics, and as a result, they should be considered as component of combined therapy which could definitely reduced the development of bacterial resistance to both enzymes and antibiotics. The preliminary research revealed that most of these enzymes can be produced using heterologous, especially Escherichia coli expression systems; however, still much effort is required to develop more efficient and large-scale production technologies. This review discusses current state on knowledge with emphasis on the possibilities of application of PHs in the context of therapeutics for infections caused by staphylococci.